Company Overview and News

19
Buy These Waters

2018-06-07 seekingalpha
The company has shown a consistent history of sales growth and ability to beat earnings estimates.
WSBF WSCC A TMO WAT SHMZF PKI BRKR MTD

10
BRKR / Bruker Corp. 8-K (Current Report)

2018-06-06 sec.gov
UNITED STATES SECURIT
BRKR

19
Bruker Unveils New Mass-Spectrometry Products, Boosts CALID

2018-06-04 zacks
Keeping in line with the company’s product expansion strategy, Bruker Corporation (BRKR - Free Report) recently introduced a broad line of mass spectrometry products and workflows at the ASMS (American Society for Mass Spectrometry) conference. The company claims these products to act as breakthroughs in life-science research, in clinical research and large-cohort validations in phenomics and proteomics, in biopharma applications and in applied toxicology and forensics markets.
AMED ISRG ILMN BRKR

22
Bruker (BRKR) Up 2.3% Since Earnings Report: Can It Continue?

2018-06-04 zacks
It has been about a month since the last earnings report for Bruker Corporation (BRKR - Free Report) . Shares have added about 2.3% in that time frame.
AVP BRKR

10
BRKR / Bruker Corp. SD

2018-05-31 sec.gov
UNITED STATES
BRKR

10
BRKR / Bruker Corp. 8-K (Current Report)

2018-05-21 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISS
BRKR

10
BRKR / Bruker Corp. 10-Q (Quarterly Report)

2018-05-10 sec.gov
Table of Contents
BRKR

92
Bruker (BRKR) Q1 Earnings & Revenues Beat, Margins Expand

2018-05-07 zacks
Bruker Corporation (BRKR - Free Report) reported adjusted earnings per share (EPS) of 24 cents in the first quarter of 2018, up 26.3% from the year-ago figure. Also, adjusted EPS beat the Zacks Consensus Estimate by a couple of cents.
UNP ODP BAX ISRG CHE RDUS BRKR

10
Bruker Corporation 2018 Q1 - Results - Earnings Call Slides

2018-05-04 seekingalpha
The following slide deck was published by Bruker Corporation in conjunction with their 2018 Q1 earnings call.
BRKR

10
Bruker (BRKR) Q1 2018 Results - Earnings Call Transcript

2018-05-04 seekingalpha
Good day, everyone, and welcome to the Bruker Corporation First Quarter 2018 Earnings Conference Call. All participants will be in listen-only mode. After today's presentation, there will be an opportunity to ask questions. And please note that today's event is being recorded.
BRKR

11
BRKR / Bruker Corp. 8-K (Current Report)

2018-05-03 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISS
BRKR

10
BRIEF-Bruker Acquires Nanoir Company Anasys Instruments

2018-04-17 reuters
* BRUKER CORP - FINANCIAL DETAILS OF TRANSACTION WERE NOT DISCLOSED. Source text for Eikon: Further company coverage:
BRKR

10
BRKR / Bruker Corp. DEF 14A

2018-04-17 sec.gov
QuickLinks -- Click here to rapidly navigate through this document
BRKR

53
NN, Inc: ~50% Upside For Misunderstood Industrial

2018-03-20 seekingalpha
NN, Inc. is a serial acquirer and has built a track record of building a reputable set of businesses.
CNMD GGG B SYK ITW CW MLAB BRKR NNBR NNGPF NDSN

12
BRKR / Bruker Corp. 10-K (Annual Report)

2018-03-16 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS ITEM 8 FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
BRKR

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

8h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

9h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 116794108